Fierce Pharma June 24, 2024
Despite coming to market second, Bristol Myers Squibb’s Mirati Therapeutics-inherited cancer med Krazati has gained the lead on its Amgen rival Lumakras in a heated KRAS race.
Late Friday, the U.S. FDA granted an accelerated approval for BMS’ KRAS inhibitor Krazati plus Eli Lilly’s Erbitux (cetuximab) to treat certain chemotherapy-experienced adults with KRAS-mutated locally advanced or metastatic colorectal cancer (CRC). Given that the approval is accelerated, BMS may have to further prove Krazati’s merit in CRC in a confirmatory trial to keep hold of the green light.
The new nod comes after Krazati’s initial approval in previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC) in Dec. 2022. Krazati, also known as adagrasib, was the second KRAS-targeting drug to hit...
Today's Sponsors
Today's Sponsor